ReviewClinical Medicine Insights. Cardiology2025
Two Sides of Triglycerides in Atherogenesis: An Essential Contributor.
Review in Clinical Medicine Insights. Cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atherosclerosis is chronic arterial wall damage, which often results in cardiovascular disease development. Since atherosclerosis is almost asymptomatic, it is difficult to detect this condition, but it is even more difficult to deal with the consequences. The reasons for the development of atherosclerosis are still not completely clear, but the mechanisms involved in atherogenesis are known. Among them, lipid metabolism alterations, oxidative stress, as well as impaired mitochondrial function take pride of place. In our review, we want to dwell in more detail on such a component as lipid metabolism disorders. In particular, triglycerides, their levels, and influence on the development of the disease. Triglycerides provide the second-largest source of energy. In the context of atherosclerosis, the question arises, is an increase in the level of triglycerides in the blood a cause, a biomarker, or a consequence of the processes accompanying atherogenesis?
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.